phrykt

Mereo BioPharma Group plc (MREO): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of MREO were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Mereo BioPharma Group

From the latest filings

Overall: about as much buying as selling. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MREO

57 funds and institutions reported MREO shares worth $18M at the end of Q2 2026, about 7% of the company. The largest holder is Rubric Capital Management LP with 1.9%.

Funds and institutions (13F) 7%Everyone else 93%

10 largest owners, by share of the company

Rubric Capital Management LP1.9%
683 Capital Management, LLC1.5%
Bank of America Corp1.0%
Defilade Capital Management, L.P.0.9%
Newtyn Management, LLC0.4%
Tejara Capital Ltd0.3%
UBS Group AG0.2%
Two Sigma Investments, LP0.2%
EcoR1 Capital, LLC0.1%
Jane Street Group, LLC0.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Rubric Capital Management LP15.31M1.92%$4.9MNo change
683 Capital Management, LLC11.78M1.48%$3.7M-2%
Bank of America Corp8.20M1.03%$2.6MNo change
Defilade Capital Management, L.P.7.56M0.95%$2.4MNo change
Newtyn Management, LLC3.00M0.38%$953K-58%
Tejara Capital Ltd2.04M0.26%$647KNo change
UBS Group AG1.45M0.18%$460K-3%
Two Sigma Investments, LP1.32M0.17%$419K+602%
EcoR1 Capital, LLC1.00M0.13%$318K-93%
Jane Street Group, LLC774,9440.10%$246K+454%
Ishara Investments LP768,7500.10%$244KNew
Wealthspire Advisors, LLC765,0000.10%$243K-4%
Citadel Advisors LLC444,1580.06%$141KNew
Rangeley Capital, LLC329,2000.04%$105KNo change
Susquehanna International Group, LLP213,2700.03%$67.8K+9%
Marshall Wace, LLP179,8840.02%$57.6K-74%
XTX Topco Ltd174,4810.02%$55.4K+107%
Group One Trading LLC167,5150.02%$53.2K-50%
State Street Corp134,7720.02%$42.8K+1%
Nomura Holdings Inc104,3610.01%$33.2KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No MREO insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MREO short interest

Low short interest. 0.4% of MREO shares are sold short: about 1 share in 238. Over the last 12 reports the number of shares short went down 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.35M MREO shares were sold short, 0.4% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 477,903 shares, buying them all back would take about 7.0 trading days (days to cover).

Shares short, % of all shares

0.42%May 15Oct 301.13%

Days to cover

7.0May 15Oct 307.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.35M0.42%+4%477,9037.0
Oct 15, 20263.23M0.40%+21%1.22M2.6
Sep 30, 20262.68M0.34%-13%2.14M1.2
Sep 15, 20263.08M0.39%-18%1.57M2.0
Aug 31, 20263.76M0.47%-13%1.10M3.4
Aug 14, 20264.32M0.54%+26%17.70M1.0
Jul 31, 20263.41M0.43%-3%1.02M3.4
Jul 15, 20263.54M0.44%-40%1.10M3.2
Jun 30, 20265.88M0.74%+10%1.85M3.2
Jun 15, 20265.35M0.67%-34%3.45M1.6
May 29, 20268.16M1.02%+44%11.05M1.0
May 15, 20265.68M0.71%-13%1.81M3.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Mereo BioPharma Group company events

Mereo BioPharma Group filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 19, 2026ListingAs previously disclosed, on February 17, 2026, Mereo BioPharma Group plc received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that it no longer met the requirement to maintain a minimum bid price of $1.00 per share for continued listing on… Filing
  3. Aug 11, 2026ResultsReleased financial results. Filing
  4. Aug 11, 2026AgreementMereo BioPharma Group plc entered into an Option and License Agreement with Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company, for the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. Filing
  5. May 14, 2026VoteReported shareholder vote results. Filing
  6. May 12, 2026ResultsAmended an earlier report. Released financial results. Filing
  7. May 12, 2026DealCompleted a purchase or sale of a business or assets. Filing
  8. Mar 27, 2026LeadershipDr. Annalisa Jenkins informed Mereo BioPharma plc. Filing
  9. Mar 19, 2026ResultsReleased financial results. Filing
  10. Feb 17, 2026ListingMereo BioPharma Group plc received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its American Depositary Shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required for continued… Filing
  11. Jan 12, 2026AnnouncementThe Company updated its previous cash runway guidance. Filing
  12. Dec 29, 2025AnnouncementThe Company announced the results from the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta (OI). Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Mereo BioPharma Group financials

Famous investors that hold MREO

2 of the 50 well-known investors we track reported holding MREO in their latest 13F filing. The largest position is Jim Simons's, worth $64.4K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026160,118$64.4K0.0%+207%
Ken Griffin · Citadel AdvisorsQ3 202642,646$17.1K0.0%-90%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MREO in the last 120 days.

FiledHolderFormStake
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A3.4%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A3.4%

Questions about Mereo BioPharma Group plc (MREO) stock

Who owns the most MREO stock?

The largest reported owner of Mereo BioPharma Group plc (MREO) is Rubric Capital Management LP, with 1.9% of the company. In total, 57 funds and institutions reported holding MREO at the end of Q2 2026, together about 7% of the shares. See the largest owners.

Are MREO insiders buying or selling?

No MREO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in MREO?

As of Oct 30, 2026, 3.35M MREO shares were sold short, 0.4% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 477,903 shares, buying them all back would take about 7.0 trading days (days to cover). See the history.

Which famous investors hold MREO?

2 of the 50 well-known investors we track reported MREO in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $64.4K. See all holders.

Executive pay

Mereo BioPharma Group's chief executive was paid a total of $2.7M for the year ended Dec 31, 2025, down 14% from $3.2M the year before. In the last 12 months, Mereo BioPharma Group's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$2.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.